Q-omics provides the consensus-scored PARD6B profile across patient tissues and cancer cell-line models. PARD6B expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, PARD6B is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, PARD6B RNA expression shows 20,875 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LIHC, KICH, and THYM as cancer lineages where PARD6B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PARD6B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PARD6B survival associations across molecular data types. PARD6B RNA expression shows survival associations in the most cancer types (28), followed by mutation status (5) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PARD6B RNA expression–survival associations across cancer types. High PARD6B expression shows unfavorable associations in LIHC, UCEC and PAAD, but favorable associations in KIRC, BRCA and MESO. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for PARD6B RNA expression.
This table summarizes PARD6B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PARD6B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PARD6B shows lower tumor expression in KICH, KIRC and LUSC and higher tumor expression in COAD, BLCA and STAD. The KICH box plot shows higher PARD6B RNA expression in normal versus tumor tissue (log2 FC = −1.551, t-test p < 0.001).
This table shows molecular features associated with PARD6B in patient tissues and cancer cell lines. In patient samples, PARD6B shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, PARD6B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
